<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="945">
  <stage>Registered</stage>
  <submitdate>14/12/2005</submitdate>
  <approvaldate>16/12/2005</approvaldate>
  <actrnumber>ACTRN12605000793617</actrnumber>
  <trial_identification>
    <studytitle>Phase I dose-escalation study for CYT997</studytitle>
    <scientifictitle>Phase I dose-escalation study of CYT997 given as a 24-hour intravenous infusion every three weeks in patients with advanced solid tumours</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Cancer - solid malignancies that are metastatic or unresectable</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Other cancer types</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>CYT997 administered as a 24 hour intravenous infusion every three weeks</interventions>
    <comparator>No control group.</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To establish the dose-limiting toxicities of CYT997 given as a 24-hour continuous intravenous infusion</outcome>
      <timepoint>From data collected during the first cycle.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>To establish the maximum tolerated dose of CYT997 given as a 24-hour continuous intravenous infusion</outcome>
      <timepoint>From data collected during the first cycle.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>(i) To study the pharmacokinetics of CYT997</outcome>
      <timepoint>From data collected during the first and second cycles.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>(ii) To characterise the toxicities and tolerability of CYT997</outcome>
      <timepoint>From data collected throughout the study.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>(iii) To define a recommended dose for Phase II studies</outcome>
      <timepoint>From data collected during the first cycle.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>(iv) To make a preliminary evaluation of anti-tumour activity</outcome>
      <timepoint>From data collected throughout the study.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>(v) To make a preliminary evaluation of vascular-targetting activity</outcome>
      <timepoint>From data collected during the first cycle.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>(vi) To assess for pharmacokinetic/pharmacodynamic relationships</outcome>
      <timepoint>From data collected during the first cycle.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>(i) Patients must have solid malignancy that is metastatic or unresectable and for which standard curative or palliative anti-neoplastic treatments do not exist or are no longer effective.(ii) Life-expectancy of greater than 3 months(iii) No anti-cancer chemotherapy or hormonal therapy for the preceding 4 weeks(iv) Patients must have adequate organ and marrow function(v) Willing to give informed consent.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>(i) Patients must not have received other investigational agents within the preceding 4 weeks(ii) Patients with known brain metastases are excluded from the trial(iii) As CYT997 may have vascular targetting activity, patients with various cardiovascular risk factors (including MI or stroke within 6 months; unstable angina; symptomatic peripheral artery disease etc) are excluded(iv) Pregnant women and patients with immune deficiency are also excluded.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Other</assignment>
    <designfeatures />
    <endpoint>Safety</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>14/06/2005</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>24</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Cytopia Research Pty Ltd</primarysponsorname>
    <primarysponsoraddress>75 Commercial Rd, Prahran, Victoria, 3004.</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Cytopia Research Pty Ltd</fundingname>
      <fundingaddress>75 Commercial Rd, Prahran, Victoria, 3004.</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>Nil</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>CYT997 is an experimental anticancer agent with vascular targetting activity.  This Phase I trial aims to determine the safety and tolerability of CYT997 when given as a 24-hour intravenous infusion.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Department of Medical Oncology Royal Brisbane and Women's Hospital</ethicname>
      <ethicaddress>Butterfield Street, Herston, Qld</ethicaddress>
      <ethicapprovaldate>5/04/2005</ethicapprovaldate>
      <hrec>2005/007</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Q-Pharm Pty Ltd</ethicname>
      <ethicaddress>300C Herston Road, Herston, Qld</ethicaddress>
      <ethicapprovaldate>15/03/2005</ethicapprovaldate>
      <hrec>H0502-005T (P857)</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Gregg Smith</name>
      <address>Cytopia Research Pty Ltd
75 Commercial Road
Prahran VIC 3004</address>
      <phone>+61 3 95226900</phone>
      <fax>+61 3 9510 9291</fax>
      <email>gregg.smith@cytopia.com.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Gregg Smith</name>
      <address>Cytopia Research Pty Ltd
75 Commercial Road
Prahran VIC 3004</address>
      <phone>+61 3 95226900</phone>
      <fax>+61 3 9510 9291</fax>
      <email>gregg.smith@cytopia.com.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Gregg Smith</name>
      <address>Cytopia Research Pty Ltd, 75 Commercial Rd, Prahran, Victoria, 3004</address>
      <phone>+61 3 9522 6900</phone>
      <fax>+61 3 9510 9291</fax>
      <email>gregg.smith@cytopia.com.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>